CAPSULES: 42. Dosage:
See prescribing information for full details. Prescribing Restrictions:
Metastatic colorectal tumors in combination with leucovorin. Contra-Indications:
Hypersensitivity, patients who are receiving or have received within the previous 4 weeks a halogenated antiviral agent. Special Precautions:
Myelosuppression, hepatic disorders and renal disorders, infectious diseases, varicella, gastric and/or duodenal ulcer, abnormal glucose tolerance, intractable vomiting, severe diarrhea, stomatitis, bleeding from any site, gastrointestinal ulcers, poor nutritional status. Side Effects:
Dehydration, severe enteritis, myelosuppression, severe hepatic disorders, somnolence, disturbances of consciousness, dysesthesia, extrapyramidal symptoms, urinary incontinence, paralysis in the extremities, speech disturbance, gait disturbance, disorientation or memory loss, leukoencephalopathy occur rarely. Interstitial pneumonia, angina, jaundice and elevated (SGOT, AST), elevations in blood urea nitrogen or creatinine levels, proteinuria and hematuria, gastrointestinal side effects, malaise and vertigo, headache, excitement, tinnitus, skin dyscrasia, acute pancreatitis, rash and pruritis, chest pain and abnormal ECG, fever, coughing/sputum, arthralgia, glycosuria, burning sensation, bloody sputum, conjunctival congestion occur rarely. Drug Interactions:
Sorivudine, phenytoin, other antineoplastic agents.